Temperature Dependence of Plasmin-Induced Activation or Inhibition of Human Platelets

By He Lu, Claudine Soria, Elisabeth M. Cramer, Jeannette Soria, J. Maclouf, Jean Y. Perrot, Hong Li, Pierre L. Commin, Friedrich Schumann, Odile Regnier, Roger H. Lijnen, and Jacques P. Caen

It is known that at 37°C plasmin may have two opposite effects on platelets: at high concentrations (>1.5 caseinolytic units [CU]/mL), plasmin activates platelets; at lower concentrations (0.1 to 1.0 CU/mL) it inhibits platelet activation induced by thrombin, collagen, or calcium ionophore A23187. In this study, we report that when lowering the incubation temperature from 37°C to 22°C resulted in an increase in the expression of fibrinogen receptors, in platelet release and aggregation. Thromboxane A, was not generated by plasmin treatment at either temperature. Ultrastructural studies showed that platelets responded to low-dose plasmin at 37°C by forming pseudopods, centralizing granules without fibrinogen release, whereas at 22°C the same dose of plasmin caused platelet degranulation with the appearance of α-granule fibrinogen within the lumen of the surface connected canaliculr system. In addition, at 22°C plasmin at doses insufficient to induce platelet aggregation potentiated platelet response to thrombin. Thus, we suggest that plasmin may initiate both activating and inhibitory processes within platelets and that the change of temperature could influence this balance. These results may be of clinical relevance, because the fibrinolytic system was found activated during cardiopulmonary bypass in which the temperature of patient’s blood circulation was reduced. This temperature-dependent behavior is also an interesting model for a further study on platelet response to serine proteases.

© 1991 by The American Society of Hematology.

MATERIALS AND METHODS

Materials. Human fibrinogen (grade L) and purified plasmin (15 CU per milligram of protein, 1.27 CU/mL equal to 1 μmol/L)
were purchased from Kabi Laboratory (Stockholm, Sweden). The protein concentration in these preparations was measured using a protein assay kit (Sigma, St Louis, MO) with the Lowry procedure. Bovine thrombin (70 U/mg) was purchased from F. Hoffmann-La Roche Co Ltd (Basel, Switzerland). Aprotinin was from Bayer Parma (Paris, France). Biotin-N-hydroxysuccinimide ester was purchased from Calbiochem (San Diego, CA) and Streptavidin-phycocerythrin was from Caltag Laboratory (San Francisco, CA). Recombinant hirudin was from Hoechst (Frankfurt, Germany).

Preparation of washed human platelets. Venous blood from healthy volunteers who had not taken aspirin or other medication known to interfere with the platelet function for at least 10 days before donation was collected into plastic tubes containing ACD buffer (6.8 mmol/L citric acid, 11.2 mmol/L trisodium citrate, 24 mmol/L glucose). The platelet-rich plasma (PRP) was obtained by centrifugation at 150 g for 10 minutes at room temperature. The isolated platelets were obtained by further centrifugation of PRP at 1,100 g for 10 minutes at room temperature and washed three times with the washing buffer (36 mmol/L citric acid, 5 mmol/L KCl, 2 mmol/L CaCl₂, 1 mmol/L MgCl₂, 103 mmol/L NaCl, 5 mmol/L glucose, pH 6.5) containing 3.5 mg/mL bovine albumin (Sigma), 7 mg/mL prostaglandin E₁ (Sigma), and 25 μg/mL apyrase (Sigma). The washed platelets were resuspended in the reaction buffer (2 mmol/L KCl, 12 mmol/L NaHCO₃, 0.3 mmol/L NaH₂PO₄, 2.9 mmol/L CaCl₂, 1 mmol/L MgCl₂, 137 mmol/L NaCl, 5.5 mmol/L glucose, 3.5 mg/mL bovine albumin pH 7.35) before each assay.

Platelet aggregation. The washed platelets were resuspended to a final concentration of 4 to 5 × 10⁹/mL in the reaction buffer. Plasmin-induced platelet aggregation was achieved by adding 20 μL of plasmin at various concentrations to 0.2 mL platelet suspension with or without incubation for 5 minutes at the indicated temperatures before stirring. The aggregation was monitored in an aggregometer (Chrono-log) at 37°C with stirring at 900 rpm. In some experiments, 10 to 20 μL of human fibrinogen (4 mg/mL) were added to the mixture. The aggregation induced by 0.5 U/mL thrombin was set up as a control. Maximal aggregation (% was calculated as a percentage of the maximal intensity of platelet aggregation induced by thrombin (0.5 U/mL). Plasmin-induced platelet aggregation was totally inhibited by aprotinin at 0.2 μmol/L, showing that it depends on the active center of plasmin.

Platelet aggregation induced by a combination of plasmin with thrombin was performed by incubating platelets for 5 minutes at 22°C with plasmin or with buffer, followed by adding thrombin to trigger aggregation with stirring. Final concentrations of plasmin and of thrombin used are indicated (see Fig 9).

Preparation of biotinylated monoclonal antibodies (MoAbs) and flow cytometric analysis. Murine AC1.2 MoAb (IgG₁), specific for PADGEM or GMP-140, was isolated from ascitic fluid by protein G-affinity chromatography and dialyzed with the reaction buffer (0.2 mol/L NaHCO₃, 0.15 mol/L NaCl, pH 8.8) overnight. Conjugation with biotin of the antibody was achieved by adding 0.1 mg biotin-N-hydroxysuccimide ester in pure dimethyl sulfoxide to 1 mg dialyzed antibody in the reaction buffer. The reaction was stopped after 15 minutes of agitation at room temperature by adding 10% 1 mol/L NH₄Cl. Free biotin was removed by 24 hour dialysis with Tyrode buffer.

Conjugation with biotin of purified PAC-1 murine MoAb (IgM), which reacts with the fibrinogen receptor located on activated glycoprotein (GP) Ibα/IIa complex on the platelet membrane, was performed as described above.

The binding assay for MoAbs to platelets was performed in Eppendorf tubes containing 50 μL Tyrode buffer and 5 μL biotinylated antibodies (7.7 μg/mL for PAC-1 and 0.6 μg/mL for AC1.2 as final concentration). If plasmin or thrombin was present in the samples, aprotinin (50 μmol/L) or hirudin (10 μg/mL) was included in Tyrode buffer to neutralize the respective enzymatic activities. Ten microliters of activated or resting platelets at 5 to 10 × 10⁹/mL was then added into the tubes and incubated for 15 minutes at room temperature. Then, 10 μL of streptavidin-phycocerythrin (PE) (1:5 diluted) was added to the mixture for another 15 minutes of incubation. The samples were then diluted with Tyrode buffer and fixed with an equal volume of phosphate-buffered saline (PBS) containing 10 mmol/L EDTA and 0.2% glutaraldehyde. Without further washing, the samples were directly analyzed in a Becton Dickinson (Sunnyvale, CA) FACStar flow cytometer with a matched computer. The platelets were distinguished from debris or "machine noise" and from red blood cells and white blood cells by setting the appropriate forward scatter and side scatter window with a side scatter threshold. PE fluorescence was detected with a 585/42 filter and fluorescence data were obtained with gain setting in the logarithmic mode. Activated platelets appeared in the same forward/side scatter window as nonactivated platelets. The microscopic examination of strongly fluorescent platelets sorted in the machine showed that more than 97% of activated platelets remained in individually separate forms. The expression of antigen on the platelet surface was represented as a mean channel number (MC) of platelet fluorescent intensity after the calculation with the computer program. The data were then calculated using the following formula for plotting:

Specific Fluorescence % = \frac{\text{MC of Tested Sample} - \text{MC of Negative Control}}{\text{MC of Positive Control} - \text{MC of Negative Control}} \times 100

Binding of PAC-1 and AC1.2 to platelets and differential releases of platelet granules. The release of the contents of α-granules, dense granules, and lysosomes and the expression of both fibrinogen receptors and PADGEM on the platelet surface were simultaneously measured as a function of the plasmin concentration used to activate platelets. One part of ACD anticoagulated PRP was preincubated with ³H-serotonin at 0.6 μmol/L (0.37 kBq/mL PRP) for 30 minutes at room temperature. Then platelets were isolated and washed as mentioned above and resuspended in Tyrode buffer at a concentration of 1.6 × 10⁹/mL. Thirty microliters of platelets was incubated for 5 minutes (except for time-dependent experiments) with an equal volume of Tyrode buffer or plasmin solution at various concentrations. Then plasmin activity was inhibited by aprotinin at a final concentration of 50 μmol/L. Ten microliters of each sample was added to both PAC-1 and AC1.2 binding assay tubes as described above. EDTA (10 mmol/L) was added to the residual samples and these samples were immediately centrifuged at 4,000g for 3 minutes for the quantifications in the supernatants of β-TG by enzyme-linked immunosorbent assay (Diagnostica Stago, Asnières, France) and N-β-acetyl glucosaminidase (NAG) activity. The amount of released β-TG and NAG was expressed as a percentage of the total content in the original platelet suspension lysed with 0.1% Triton X-100 (Touzart et Matignon, Vitry/Seine, France). After the treatment of ³H-serotonin preloaded platelets, 1% formaldehyde was added to stop the release and the platelets were centrifuged. The ³H-serotonin in the supernatants was counted and expressed as a percentage of the total amount of ³H-serotonin in the original platelet suspension.

Measurement of thromboxane B₂. Washed platelets were exposed to plasmin at different temperatures for the indicated times. In some experiments, thrombin was added to plasmin-treated platelets followed by an incubation for another 3 minutes. After an agitation for 3 minutes, the reaction was stopped by the addition of EDTA at 10 mmol/L (final concentration) followed by an immedi-
ate centrifugation at 4°C. Then thromboxane B, was measured in the supernatant with duplicate determinations as described.35

Electron microscopy. After the exposure of washed platelets to 0.2 CU/mL plasmin (or buffer for control) at 37°C or at 22°C for 5 minutes, platelets were first fixed by 1% glutaraldehyde in Tyrode buffer, washed three times with PBS, and then alternatively post fixed with 1% osmium tetroxide, stained with uranyl acetate, and embedded in Epon (Ladd Research Industry, Burlington) for standard electron microscopy or embedded in glycol methacrylate for immunoelectron microscopy. Immunostaining for fibrinogen was performed on thin sections as described previously.35 These sections were observed under a Phillips 301 electron microscope.

RESULTS

Influence of temperature on plasmin-induced platelet aggregation. At 37°C plasmin at concentrations higher than 1 CU/mL induced only weak aggregation, whereas at 22°C plasmin at lower concentrations (0.5 to 1 CU/mL) induced an immediate and strong platelet aggregation. Moreover, when preincubating platelets for 5 minutes at 22°C with plasmin before stirring in the aggregometer cuvette, the concentration of plasmin that was needed to induce platelet aggregation was reduced even further. When different concentrations of plasmin were used to activate platelets for 5 minutes at 37°C or at 22°C two dose-dependent aggregation curves were obtained (Fig 1). When platelets were treated with a fixed concentration of plasmin, the occurrence and the intensity of aggregation was temperature dependent (Fig 2). The results in Fig 2 were not modified by the addition of aprotinin and fibrinogen (0.4 mg/mL) at the end of the incubation period, indicating that the absence of aggregation at 37°C was not due to the degradation of platelet fibrinogen by plasmin.

The release reaction of platelet granules induced by plasmin was studied at different temperatures. The tests were performed at 22°C, 28°C, 32°C, and 37°C according to aggregation experiments. The results in Table 1 show that the release of serotonin from dense bodies and of N-acetyl glucosaminidase activity from lysosomes was higher at 22°C than at 37°C. Similar results were noted for PADGEM expression (Fig 3): platelets incubated for 5 minutes at 37°C with 0.2 CU/mL plasmin did not express PADGEM on the platelet membrane, whereas full expression was shown when platelets were incubated with the same amount of plasmin at 22°C. When the incubation was performed at 32°C, the expression profile showed two peaks.

The results suggest that as the temperature decreased from 37°C to 22°C, the mechanism controlling the release of platelet granules and the expression of the fibrinogen receptor were progressively modified.

Table 1. Plasmin-Induced Release of Serotonin and N-acetyl Glucosaminidase From Washed Platelets at Different Temperatures

<table>
<thead>
<tr>
<th>Temperature °C</th>
<th>Serotonin (%)</th>
<th>NAG (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>37°C</td>
<td>1.6 ± 1.3</td>
<td>0.4 ± 0.3</td>
</tr>
<tr>
<td>32°C</td>
<td>1.9 ± 1.4</td>
<td>0.2 ± 0.7</td>
</tr>
<tr>
<td>28°C</td>
<td>7.7 ± 2.3*</td>
<td>1.8 ± 0.6*</td>
</tr>
<tr>
<td>22°C</td>
<td>9.8 ± 6.0*</td>
<td>5.9 ± 0.7*</td>
</tr>
</tbody>
</table>

Washed platelets were preincubated at the indicated temperatures for 5 minutes. Then they were incubated with 0.2 CU/mL of plasmin for another 5 minutes at the indicated temperatures. After a centrifugation, released 14C-serotonin and NAG in the supernatants were measured. The data were calculated as a percentage of the total amount released from triton-lysed original platelets. Means ± SD for four different donors. The significance of the difference between means was calculated by two-way analysis of variance. *P < .05; †P < .01 to values obtained at 37°C.
EFFECT OF PLASMIN ON PLATELETS

Fig 3. Enhancement of plasmin-induced expression of PADGEM antigen on platelet surface by lowering the temperatures. Washed platelets were preincubated at the indicated temperatures for 10 minutes. Then platelets were incubated with plasmin (0.2 CU/mL) or Tyrode buffer for 5 minutes. Control nonactivated platelets (A); platelets treated with plasmin at 37°C (B), at 32°C (C), or at 22°C (D). Ten microliters of each sample was used for AC1.2 antibody-binding assay. Plasmin activity was neutralized by addition of aprotinin (final concentration, 50 μmol/L) in AC1.2 binding assay tubes. Ten thousand cells were analyzed in the flow cytometer.

Effect of plasmin on the binding of PAC-1 and AC1.2 to platelets and on the degranulation of platelets at 22°C. As plasmin degrades fibrinogen, the fibrinogen receptors induced by plasmin on platelets were studied with MoAb PAC-1, which recognizes specifically the fibrinogen receptors on GP IIb/IIIa. The amount of PAC-1 bound to the platelets treated with plasmin at 22°C was compared to the platelets activated with thrombin and ADP. The three agonists were added to the platelet suspension at relatively high concentrations to get maximal expression of fibrinogen receptors. Hirudin and aprotinin were added to neutralize thrombin and plasmin activities, respectively. As shown in Fig 4, the amount of PAC-1 bound to platelets activated by plasmin was similar to that induced by thrombin and much higher than that induced by ADP. This indicates that plasmin and thrombin are capable of inducing more fibrinogen-binding sites on platelets than ADP.

Figure 5 showed that platelets released their contents from α-granules (PADGEM expression), dense granules (serotonin), and lysosomes (NAG), and expressed fibrinogen-binding sites (PAC-1–binding sites) in response to plasmin at 22°C dose dependently. Expression of PADGEM correlated well to the curve of β-TG release (not shown). The binding of PAC-1 and AC1.2 MoAbs to platelets was found to be parallel during activation induced by plasmin at 22°C (Fig 6), suggesting that during platelet activation by plasmin at 22°C there was a large exposure of fibrinogen receptors on GP IIb/IIIa initially located in α-granules, as already described for thrombin-treated platelets.

Thromboxane B₂ synthesis by plasmin-treated platelets. It has been reported previously that plasmin does not induce thromboxane synthesis. Schafer and Adelman found that the arachidonic acid metabolism of platelets was impaired by plasmin treatment, and they suggested that this impair-
different temperatures. The results (Table 2) indicate that plasmin did not reduce the amount of bound antibodies was presented as a percentage of the highest value (mean channel number) of fluorescent intensity obtained in platelets stimulated by 1.0 U/mL thrombin. Means of two experiments.

ment was responsible for the inhibition of platelet response to thrombin, collagen, and A 23187. We examined the thromboxane synthesis in plasmin-treated platelets at different temperatures. The results (Table 2) indicate that plasmin did not induce platelet thromboxane B2 generation at 37°C nor did it at 22°C. To further test the activity of the arachidonic acid metabolism in plasmin-treated platelets under our experimental conditions, thrombin was added to plasmin-treated platelets to induce thromboxane synthesis. The results in Table 3 show that plasmin did not reduce the thromboxane formation after thrombin stimulation.

Ultrastructural observation of platelets treated by plasmin at different temperatures. Electron microscopy observation of control platelets at 22°C and at 37°C showed no sign of activation (Fig 7, A and B). At 37°C all the platelets had a discoid shape, no pseudopods, the marginal band of microtubules was located in the periphery, and granules were scattered in the cytoplasm. At 22°C some pseudopods were observed. After being exposed to 0.2 CU/mL plasmin at 37°C, activation was evidenced by the loss of discoid form, pseudopod formation, and centralization of the granules surrounded by differently oriented microtubules (Fig 7C). When platelets were exposed to the same concentration of plasmin at 22°C, the morphology of platelets was different because apart from the emission of pseudopods, a process of degranulation was clearly shown: the channels of the surface connected canalicular system (SCCS) were filled with dense material, and a large number of platelets were almost empty (Fig 7D). Fibrinogen was restricted in α-granules (Fig 8A) and was absent in SCCS after plasmin treatment at 37°C. When platelets were treated with plasmin at 22°C, few fibrinogen-containing granules remained in the cytoplasm and a large amount of fibrinogen was present in the lumen of the SCCS (Fig 8B). However, dense bodies were often observed (Fig 8C).

Platelet aggregation induced by a combination of plasmin with thrombin. Plasmin-treated platelets at 37°C were shown to be resistant to thrombin activation.45,7 However, at 22°C pretreatment of platelets with plasmin at concentrations lower than that inducing platelet aggregation (0.01 CU/mL) potentiated platelet aggregation by thrombin (Fig 9A). The addition of thrombin (0.01 U/mL) also enhanced plasmin-induced platelet aggregation (Fig 9B).

**DISCUSSION**

The plasmin-induced platelet activation has been studied in vitro at different temperatures because platelets may be exposed to plasmin in a clinical condition, like open heart surgery using cardiopulmonary bypass.27 and in thrombolytic therapy.7 However, published results of in vitro studies indicate the inconsistent platelet responses to different concentrations of plasmin. Some investigators reported10,12 that plasmin induced platelet aggregation and degranulation. Others13,15 showed that thrombolytic agents

![Graph showing percent specific fluorescence over time](https://example.com/graph.png)

**Table 2. Effect of Plasmin on Thromboxane B2 Generation at Different Temperatures**

<table>
<thead>
<tr>
<th>Treatment</th>
<th>22°C</th>
<th>25°C</th>
<th>37°C</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plasmin + agitation</td>
<td>9.7</td>
<td>16.0</td>
<td>18.0</td>
</tr>
<tr>
<td>Plasmin - agitation</td>
<td>7.5</td>
<td>11.7</td>
<td>21.3</td>
</tr>
<tr>
<td>Buffer control</td>
<td>8.3</td>
<td>11.3</td>
<td>24.7</td>
</tr>
<tr>
<td>Thrombin 0.4 U/mL</td>
<td>ND</td>
<td>ND</td>
<td>1,106.0</td>
</tr>
</tbody>
</table>

Washed platelets were preincubated with Tyrode buffer for 5 minutes at the indicated temperatures. Then they were incubated with plasmin (0.2 CU/mL) at the indicated temperatures for another 5 minutes followed by an agitation or an incubation (as indicated) for 3 minutes in an aggregometer. Reaction was stopped after 8 minutes by addition of 10 mmol/L EDTA, and the samples were centrifuged immediately. Thromboxane B2 concentration in the supernatants was measured. The mean values were calculated from four donors.

![Table showing effect of plasmin on thrombin-induced platelet thromboxane B2 generation](https://example.com/table.png)

**Table 3. Effect of Plasmin on Thrombin-Induced Platelet Thromboxane B2 Generation**

<table>
<thead>
<tr>
<th>Concentration (U/mL)</th>
<th>Normal Control</th>
<th>Plasmin Treated</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thrombin 0</td>
<td>5.7 ± 7.2</td>
<td>10.2 ± 9.9</td>
</tr>
<tr>
<td>Thrombin 0.06</td>
<td>36.4 ± 35.5</td>
<td>64.9 ± 52.2</td>
</tr>
<tr>
<td>Thrombin 0.1</td>
<td>219.8 ± 49.2</td>
<td>268.9 ± 62.7</td>
</tr>
<tr>
<td>Thrombin 0.4</td>
<td>1,688.0 ± 424.6</td>
<td>1,161.3 ± 363.1</td>
</tr>
</tbody>
</table>

Washed platelets preincubated with Tyrode buffer in 37°C were incubated with either 0.3 CU/mL plasmin or Tyrode buffer at 37°C for 15 minutes, then aprotinin (final concentration 10 μmol/L) and thrombin were added. After agitation for 3 minutes in the aggregometer, the reaction was stopped by addition of EDTA at 10 mmol/L (final concentration), and the samples were centrifuged immediately. Thromboxane B2 was measured in the supernatants. Means ± SD for three different donors.
Fig 7. Ultrastructure of plasmin-treated platelets at different temperatures. Washed platelets were preincubated at the indicated temperatures for 5 minutes. Then platelets were incubated with plasmin (0.2 CU/mL) or buffer at the different temperatures for 5 minutes. (A) Control platelets at 37°C: they exhibit an even and regular elliptic shape and display numerous α-granules and scant SCCS (arrows); (B) control platelets at 22°C: they show uneven shape with few pseudopods (arrowheads); (C) platelets treated with plasmin at 37°C: signs of platelet activation, eg, numerous pseudopods (arrowheads) and granule centralization. The SCCS is empty (arrows); (D) platelets treated with plasmin at 22°C: platelet activation is intense with long and numerous pseudopods (arrowheads), less granules in the cytoplasm, and large SCCS cisternae filled with dense material (arrows). (Original magnification × 20,000.)
led to an inhibited platelet aggregation and degranulation in response to thrombin, ADP, collagen, and A23187.

Our experiments performed at 37°C confirm previous observations: platelet aggregation did not occur when incubating washed platelets with plasmin at low concentrations (<1.0 CU/mL) for 5 minutes, but did occur at plasmin concentrations higher than 1.0 CU/mL. However, we found that the change in the incubation temperature could modify the platelet response to plasmin stimulation as shown in Figs 1 and 2 with a temperature-dependent platelet aggregation, and in Table 1 showing a temperature-dependent release reaction. At 22°C with incubation, plasmin induced strong aggregation even at a low concentration (<0.1 CU/mL). We also found that at 22°C plasmin potentiated platelet response to thrombin. The decrease in platelet response to plasmin at 37°C is not related to the digestion of platelet fibrinogen or of fibrinogen receptors by plasmin. These can be excluded for two reasons: Firstly, the addition of fibrinogen plus aprotinin in aggregation tests failed to induce aggregate formation of platelets pretreated with plasmin at 37°C. Secondly, the addition of fibrinogen into platelets that were treated with a high concentration of plasmin for at least 2 hours triggered perfect aggregation, indicating that fibrinogen receptors resisted plasmin digestion. Thus, these findings demonstrate for the first time that plasmin-induced platelet activation is temperature dependent.

Our experiments performed at 22°C showed a much stronger positive response of washed platelets to plasmin than those reported in the literature in which the studies were conducted at 37°C. At a concentration of plasmin below 1 CU/mL, we showed a dose-dependent platelet aggregation accompanied by an expression of fibrinogen receptors (PAC-1 binding) and by a release of α-granules with PADGEM expression, dense granules, and lysosomes. Furthermore, at 22°C the amount of fibrinogen receptors on platelets activated by plasmin was similar to that on platelets activated by thrombin and was much higher than that on platelets induced by ADP. The fibrinogen receptors on platelet-activated platelets could be detected at plasmin concentrations below 0.05 CU/mL. Thus, plasmin can probably induce the conformational change of GP IIb/IIIa when release reaction has not yet occurred. Further exposure of PAC-1 binding sites on platelet-activated platelets was noted at the higher concentrations of plasmin and accompanied by expression of PADGEM antigen on plate-
EFFECT OF PLASMIN ON PLATELETS

Fig 9. Induction of platelet aggregation by a combination of plasmin with thrombin. Washed platelets (4 x 10⁶/mL) were incubated with plasmin for 5 minutes at 22°C. Aggregation was triggered by the addition of thrombin and stirring. (A) Platelets were incubated with plasmin at a fixed final concentration (0.01 CU/mL) or buffer and platelet aggregation was triggered by various concentrations of thrombin (at indicated final concentrations). (B) Platelets were incubated with various concentrations of plasmin (at indicated final concentrations) and platelet aggregation was triggered by stirring in the absence or presence of a fixed concentration of thrombin (0.01 CU/mL). Aggregation rate was calculated with the velocity of each curve and expressed as a percentage of the velocity obtained from thrombin (0.5 U/mL) stimulated platelet aggregation. Means ± SD for six donors in each panel.

Platelet activation is a complex process. The initiation of thromboxane synthesis in platelets is a common feedback pathway that provokes full activation. The results showed that the treatment of platelets by plasmin either at 37°C or at 22°C failed to induce the thromboxane generation, whereas a normal amount of thromboxane B₂ was observed with plasmin-treated or nontreated platelets after thrombin stimulation. Thus, strong platelet activation induced by plasmin at 22°C was not mediated by the thromboxane B₂ pathway.

Taking our results and other published results together, we suggest that plasmin may initiate concomitantly both activating and inhibitory processes that are influenced by temperature. Adnot et al found that plasmin may induce an elevation of the local cAMP concentration, indicating the possibility that cAMP is implicated in this inhibitory process.

Although full understanding of the biologic basis of plasmin-induced platelet activation and inhibition deserves further investigation, these results might help in understanding platelet activation during open-heart surgery using cardiopulmonary bypass (CPB). The hemostatic defect leading to heavy blood loss and prolonged postoperative bleeding in this type of surgery is a well-known clinical observation. A concomitant increase in fibrinolytic activity and platelet activation during CPB has been described. Activated platelets were detected using flow cytometric analysis during CPB. Our results lead us to suggest that platelet activation during CPB is related to the influence of temperature on platelet activation in response to generated plasmin, because the temperature of patient’s blood circulation using extracorporeal circulation (ECC) is maintained around 28°C to 32°C. Tanaka et al related the decrease in platelet count to the activation of fibrinolysis and coagulation during CPB despite the use of heparin. Our results provide further evidence that platelets are more easily activated in the presence of generated plasmin plus thrombin at the temperature maintained during CPB. As a consequence, by exposure of the receptors for fibrinogen and PADGEM antigen, which mediate adhesion of activated platelets to neutrophils and monocytes, these activated platelets may be quickly eliminated from the blood circulation.

In this context, the temperature-dependent influence of
platelet activation induced by plasmin. This phenomenon
retically, one can suggest that platelet activation induced by
minimize the rate of reocclusion, the administration of
E,,38,39 proteinase inhibitor with strong plasmin-inhibiting capac-
tance of temperature in determining the occurrence of
thrombolysis and reduced the occurrence of reocclusion.
In brief, our studies show, for the first time, the impor-
tance of temperature in determining the occurrence of
platelet activation induced by plasmin. This phenomenon
may be related to the alteration by temperature of plasmin-
triggered platelet activating and inhibitory processes. This
finding is relevant to the clinical practice such as CPB,
blood platelet preservation in the cold40 and thrombolytic
therapy. The interaction of the fibrinolytic system and
platelets may be an important mechanism regulating the
balance between hemostasis and thrombolysis. There is no
doubt that further detailed investigations of this mechanism
will yield substantial benefit for medical practice.

ACKNOWLEDGMENT

We thank Dr Sanford J, Shattil of Hematology-Oncology Sec-
tion, Department of Medicine and the Coagulation-Thrombosis
Laboratory, University of Pennsylvania, Philadelphia, for providing
PAC-1 monoclonal antibody and very helpful communication; Drs
Bruce Furie and Alessandro Celi of Division of Hematology-
Oncology, Tufts University, Boston, MA, for providing AC1.2
monoclonal antibody; Dr Jacques H.M. Cohen of C.H.U. in Reims,
Serbio Laboratory, Gennnevilliers, France, for the assistance in the
use of flow cytometer; Daniele Tenza and Dr Jacques Maclouf of
INSERM U 150, Paris, for the works of electron microscopy and
thromboxane B, measurement.

REFERENCES

1. Bachmann F: Fibrinolysis, in Verstraete M, Vermuylen J,
   Lijnen HR, Arnout J (eds): Thrombosis and Haemostasis.
   Leuven, Belgium, International Society on Thrombosis and
   Haemostasis and Leuven University, 1987, p 227
   1989
3. Vaughan DE, Mendelsohn ME, Declerck PJ, Van Houtte E,
   Collen D, Loscalzo J: Characterization of the binding of human
   tissue-type plasminogen activator to platelets. J Biol Chem 264:
   15869, 1989
4. Miles LA, Plow EF: Platelets bind plasminogen and potenti-
ate its activation. Haemostasis 14:48, 1984
5. Adelman B, Rizk A, Hanners E: Plasminogen interaction
6. Deguchi K, Murashima S, Shirakawa S, Soria C, Soria J,
   Dunn F, Tobelem G: The potentiating effect of platelet on
   plasminogen activation by tissue plasminogen activator. Thromb
   Res 40:853, 1985
7. Vaughan DE, Loscalzo J: Comparative effects of plasminogen
8. Krutthof EKO, Tran-Thanh C, Bachmann F: Studies on the
   release of a plasminogen activator inhibitor by human platelets.
   Thromb Haemost 55:201, 1986
9. Plow EF, Collen D: The presence and release of alpha-
10. Niewiarowski S, Senyi AF, Gillies P: Plasmin-induced plate-
    let activation and release reaction. Effect on hemostasis. J Clin
    Invest 52:1647, 1973
11. Schafer A, Maas AN, Ware JA, Johnson PC, Rittenhouse
    SE, Salzman EW: Platelet protein phosphorylation, elevation
    of cytosolic calcium, and inositol phospholipid breakdown in platelet
    activation induced by plasmin. J Clin Invest 78:73, 1986
12. Guccione MA, Kinlough-Rathbone RL, Packham MA, Har-
    fenst EJ, Rand ML, Greenberg JP, Perry DW, Mustard JF: Effects
    of plasmin on rabbit platelets. Thromb Haemost 53:8, 1985
    thrombin-induced platelet aggregation. Thromb Diath Haemorrh
    33:286, 1975
    function and of arachidonic acid metabolism. J Clin Invest 75:456,
    1985
    streptokinase of human platelet aggregation and thromboxane A,
16. Schafer A, Zavoico GB, Loscalzo J, Maas AK: Synergistic
    inhibition of platelet activation by plasmin and prostaglandin I2.
    Blood 69:1504, 1987
17. Adnot S, Ferry N, Hanoune J, Lacombe ML: Plasmin: A
    possible physiological modulator of the human platelet adenylate
18. Adelman B, Michelson AD, Loscalzo J, Greenberg J,
    Handin RI: Plasmin effect on platelet glycoprotein Ib-von Wille-
    brand factor interactions, Blood 65:32, 1985
    Role of fibrinogen in plasmin-induced platelet aggregation, in
    4: Current Basic and Clinical Aspects (Excerpta Redus). New
    York, NY, Oxford, 1990, p 81
20. Patscheke H, Worner P: Platelet activation detected by
    Role of active center and lysine binding sites of plasmin in plasmin-induced platelet activation and disaggregation. Thromb
    Haemost (in press)
    R, Wagner DD, Furie B: PADGEM protein: A receptor that
    mediates the interaction of activated platelets with neutrophils and
23. Shattil SJ, Hoxie JA, Cunningham M, Lases LF: Changes in
    the platelet membrane glycoprotein Ib/IIa complex during platelet
24. Dangelmarier CA, Holmsen H: Determination of acid
25. Pradelles P, Gress J, Maclouf J: Enzyme immunooassays of
    cicosanoids using acetylcholine esterase as label: An alternative to
    Gorius J: Gray platelet syndrome: Immunoelectron microscopic
    localization of fibrinogen and von Willebrand factor in platelets and
27. Tanaka K, Moriizato T, Yada J, Kusagawa M, Deguch K:
    Physiologic role of enhanced fibrinolytic activity during cardiopul-

From www.bloodjournal.org by guest on October 3, 2017. For personal use only.


37. ISIS-2 Collaborative Study Group: Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction-ISIS-2. Lancet 2:349, 1988


Temperature dependence of plasmin-induced activation or inhibition of human platelets

H Lu, C Soria, EM Cramer, J Soria, J Maclouf, JY Perrot, H Li, PL Commin, F Schumann and O Regnier